Drugs / SHR-1894
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07414602 | Mar → Oct 2026 expected | dermatitis | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-1894 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07414602 ↗ |
| Route | Subcutaneous | “Single Subcutaneous Dose” NCT07414602 ↗ |